Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lithium shows neuroprotective effects for neurodegenerative diseases like Alzheimer's and Parkinson's. This review supports lithium as a potential therapeutic agent for these conditions.
Area Of Science
- Neuroscience
- Pharmacology
Background
- Neurodegenerative diseases, including Alzheimer's (AD) and Parkinson's (PD), represent a significant global health challenge.
- The therapeutic potential of lithium for neuroprotection in these conditions is an area of active scientific investigation.
Approach
- A systematic review and meta-analysis of pre-clinical and clinical studies were conducted following PRISMA guidelines.
- Literature searches were performed across major databases (PubMed, EMBASE, Web of Science, Cochrane Library).
- The analysis included 32 identified articles, with 17 pre-clinical studies undergoing meta-analysis.
Key Points
- Lithium treatment demonstrated significant neuroprotective effects in animal models of AD and PD.
- In AD models, lithium reduced amyloid-beta and tau levels, improving cognitive function.
- In PD models, lithium increased tyrosine hydroxylase levels and enhanced motor behavior.
Conclusions
- The findings support lithium's therapeutic potential for neurodegenerative diseases.
- Evidence suggests positive effects of lithium in AD patients, warranting further clinical investigation.
- Lithium may offer a viable therapeutic strategy for managing Alzheimer's and Parkinson's disease.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
The cephalic phase is a conditioned or learned response to familiar foods. Our appetite or desire for a particular food modifies the preparatory responses directed by the brain. Individuals may produce more saliva and stomach...